| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50a9236cc40714de397092f5e3384872
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c17911ea3f29070e8e6f522033c697e7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5152
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20034 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-13
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-702 |
| filingDate |
2022-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bab3843e95abaf6eec463decd02b5e1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6661e783955b66e905a27687768d9c57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee01c20ae61d16adac2771b977d3536c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b210fe8cacc39cde3c08399ed8475658 |
| publicationDate |
2022-09-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022197599-A1 |
| titleOfInvention |
Cancer vaccine and method of use thereof |
| abstract |
The present disclosure generally relates to a personalized cancer vaccine having attenuated cancer cells transfected with at least one expression construct. The expression construct is capable of secretory expression of an antigenic polypeptide that could be derived from a protein from a virus. The personalized tumor vaccine, when administered to a subject in need thereof, is effective to activate an immune response. |
| priorityDate |
2021-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |